Five things for pharma marketers to know: Monday, October 3, 2016

1. Brand-name drugmakers are increasingly filing lawsuits against other brand-name drugmakers to prevent biosimilar competition. AbbVie has filed a lawsuit seeking to enforce patent protection for Humira to an effort to prevent competition from an Amgen biosimilar that received FDA approval in September. (Reuters)

2. A pair of studies found that nearly 40% of patients participating in a clinical trial for dupilumab, a treatment for atopic dermatitis developed by Regeneron and Sanofi, reported that all or most of their rash disappeared. The FDA is expected to decide whether to approve the drug in March. (NYT)

3. AstraZeneca licensed an experimental treatment for patients with moderate-to-severe Crohn's diseaseto Allergan. Allergan paid $250 million upfront, with plans for up to $1.27 billion in potential milestone payments. (Reuters)

4. Drugmakers are again blaming pharmacy benefit managers for rising drug prices, saying that wholesalers, pharmacies, and PBMs take a cut of each prescription's cost. PBMs usually receive a rebate from pharmaceutical companies based on the percentage of the therapy's list price, which means the higher the price of the drug, the higher the rebate. (WSJ)

5. An academic research project, called the Metastatic Breast Cancer Project, has enrolled 2,600 patients using word of mouth and social media. The program, which allows patients to sign up online and mail in saliva kits for genetic testing, aims to address a gap  research funding for metastatic breast cancer. (AP)